Shots:
- The topline P-III (EPCORE DLBCL-4) trial results assessed epcoritamab + lenalidomide vs rituximab + gemcitabine + oxaliplatin (R-GemOx) in adults with R/R DLBCL who received ≥1L prior of therapy
- Trial met its 1EP, significantly improving PFS & reducing the risk of disease progression or death by 60% (US censoring) & 56% (ex-US censoring). AbbVie & Genmab will engage regulators on next steps, with data to be presented at a future medical meeting
- Epcoritamab is a SC DuoBody IgG1 bispecific antibody that binds CD3 on T cells & CD20 on B cells to induce T-cell–mediated killing of CD20+ cells
Ref: PRnewswire | Image: AbbVie & Genmab | Press Release
Related News: AbbVie’s Maviret Receives EC Approval for Acute Hepatitis C Virus Infection
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
